PMID- 33100972
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201028
IS  - 1662-5102 (Print)
IS  - 1662-5102 (Electronic)
IS  - 1662-5102 (Linking)
VI  - 14
DP  - 2020
TI  - Intracerebral Transplants of GMP-Grade Human Umbilical Cord-Derived Mesenchymal 
      Stromal Cells Effectively Treat Subacute-Phase Ischemic Stroke in a Rodent Model.
PG  - 546659
LID - 10.3389/fncel.2020.546659 [doi]
LID - 546659
AB  - In subacute and chronic phases of the stroke, there are no therapeutics available 
      at present to promote functional recovery. Human umbilical cord-derived 
      mesenchymal stromal cells (hUC-MSCs) are one of the candidate cell types for 
      treating subacute-phase stroke. The benefits of cell-based therapy largely depend 
      on the migratory capacity of products administered, as well as their potential 
      for engraftment in targeted tissues and paracrine activities. Timing and delivery 
      modes may also influence the outcomes of stem-cell therapy. Still, the functional 
      recuperative effects of differing hUC-MSC delivery modes, about cell replacement 
      and cell-to-cell paracrine activity levels, have yet to be clarified in subacute 
      phases of stroke.This study was conducted to compare the therapeutic effects of 
      various delivery routes when administering Good Manufacturing Practice 
      (GMP)-grade hUC-MSCs in a rodent model of subacute-phase stroke. Cell aliquots (1 
      x 10(6)) were given to rats as intravenous (IV) injections or intracerebral (IC) 
      transplants 1 week after middle cerebral artery occlusion (MCAo). Transplanted 
      rats were examined up to 7 weeks later using various behavioral tests and 
      immunohistochemical analyses. Most IC-transplanted cells survived for short 
      periods (i.e., <4 weeks after receipt) and gradually disappeared, whereas 
      IV-injected cells were undetectable in the brain at the same time points (i.e., 3 
      days, 4 weeks, or 7 weeks after injection). Although short-lived, IC-transplanted 
      cells effectively improved behavioral deficits, serving to reduce infarct volumes 
      and glial scar formation, increase subventricular counts of proliferating 
      neuroblasts, and promote cerebrovascular ingrowth in ischemic penumbra regions. 
      IV injection, however, failed to improve behavioral function or histologic 
      parameters during the same 7-week time frame. These findings overall suggest that 
      IC transplantation is preferable to IV injection for delivery of hUC-MSCs during 
      subacute phases of stroke.
CI  - Copyright (c) 2020 Noh, Oh, Park and Song.
FAU - Noh, Jeong-Eun
AU  - Noh JE
AD  - Department of Biomedical Science, CHA Stem Cell Institute, CHA University, 
      Seongnam-si, South Korea.
FAU - Oh, Seung-Hun
AU  - Oh SH
AD  - Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam-si, 
      South Korea.
FAU - Park, In-Hyun
AU  - Park IH
AD  - Department of Genetics, Yale Stem Cell Center, Yale School of Medicine, New 
      Haven, CT, United States.
FAU - Song, Jihwan
AU  - Song J
AD  - Department of Biomedical Science, CHA Stem Cell Institute, CHA University, 
      Seongnam-si, South Korea.
AD  - iPS Bio, Inc., Seongnam-si, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20200925
PL  - Switzerland
TA  - Front Cell Neurosci
JT  - Frontiers in cellular neuroscience
JID - 101477935
PMC - PMC7546889
OTO - NOTNLM
OT  - GMP (good manufacturing process)
OT  - intracerebral transplantation
OT  - mesenchyaml stem cells
OT  - stroke
OT  - umbilical cord (UC)
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
PMCR- 2020/01/01
CRDT- 2020/10/26 05:21
PHST- 2020/03/29 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/10/26 05:21 [entrez]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fncel.2020.546659 [doi]
PST - epublish
SO  - Front Cell Neurosci. 2020 Sep 25;14:546659. doi: 10.3389/fncel.2020.546659. 
      eCollection 2020.